Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2023-09-05 (endpts.com)
Biogen secures $1.5B loan to fund Reata buyout, with three-year repayment schedule baked in
Biogen has lined up a $1.5 billion term loan to fund its $7.3 billion acquisition of Reata Pharmaceuticals. The company had made clear its intentions to finance the acquisition with both cash and debt in its August announcement.
Read more
2023-07-31 (bnnbloomberg.ca)
Biogen Aims to Replace $1.5 Billion M&A Bridge With Term Loans - BNN Bloomberg
Biogen Inc. plans to replace the $1.5 billion debt financing it secured for its purchase of Reata Pharmaceuticals Inc. with two term loans, according to a spokesperson for the company.
Read more
2023-07-28 (bloomberglaw.com)
Biogen to Buy Reata for $7.3 Billion in Rare-Disease Expansion
Biogen Inc. agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion including debt to expand its rare disease treatments in one of its biggest-ever acquisitions.
Read more
2020-06-07 (citybizlist.com)
Bristol-Myers Squibb: Growth And Valuation Trump Other Concerns
By Chuck Walston SA Summary While the Celgene acquisition added blockbusters to the company’s product portfolio, it comes with big debt and integration risk. Bristol’s top three drugs provide 69% of revenues. The patent cliffs are roughly a half
Read more